[1]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Non-alcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 4, 73-84. https://doi.org/10.1002/hep.28431
|
[2]
|
Fouad, Y., Waked, I., Bollipo, S., Gomaa, A., Ajlouni, Y. and Attia, D. (2020) What’s in a Name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver International, 40, 1254-1261. https://doi.org/10.1111/liv.14478
|
[3]
|
Fujii, H., Kawada, N. and Japan Study Group of Nafld (JSG-NAFLD) (2020) The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. International Journal of Molec-ular Sciences, 21, Article No. 3863.
https://doi.org/10.3390/ijms21113863
|
[4]
|
Leung, J.C., Loong, T.C., Wei, J.L., Wong, G.L., Chan, A.W., Choi, P.C., Shu, S.S., Chim, A.M., Chan, H.L. and Wong, V.W. (2017) Histological Severity and Clinical Outcomes of Non-alcoholic Fatty Liver Disease in Nonobese Patients. Hepatology, 65, 54-64. https://doi.org/10.1002/hep.28697
|
[5]
|
Golabi, P., Rhea, L., Henry, L. and Younossi, Z.M. (2019) Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. Hepatology International, 13, 688-694. https://doi.org/10.1007/s12072-019-09995-8
|
[6]
|
Prasoppokakorn, T., Pitisuttithum, P. and Treeprasertsuk, S. (2021) Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Journal of Clinical and Translational Hepatology, 9, 939-946. https://doi.org/10.14218/JCTH.2021.00189
|
[7]
|
Lazarus, J.V., Ekstedt, M., Marchesini, G., Mullen, J., Novak, K., Pericàs, J.M., Roel, E., Romero-Gómez, M., Ratziu, V., Tacke, F., Cortez-Pinto, H. and Anstee, Q.M. (2020) A Cross-Sectional Study of the Public Health Response to Non-Alcoholic Fatty Liver Disease in Europe. Journal of Hepa-tology, 72, 14-24.
https://doi.org/10.1016/j.jhep.2019.08.027
|
[8]
|
Fan, J.G., Kim, S.U. and Wong, V.W. (2017) New Trends on Obesity and NAFLD in Asia. Journal of Hepatology, 67, 862-873. https://doi.org/10.1016/j.jhep.2017.06.003
|
[9]
|
Lazo, M., Hernaez, R., Eberhardt, M.S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F.L. and Clark, J.M. (2013) Prevalence of Nonalcoholic Fatty Liver Disease in the United States: The Third National Health and Nutrition Examination Survey, 1988-1994. American Journal of Epidemi-ology, 178, 38-45.
https://doi.org/10.1093/aje/kws448
|
[10]
|
Lonardo, A., Byrne, C.D., Caldwell, S.H., Cortez-Pinto, H. and Targher, G. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease: Meta-Analytic Assessment of Prevalence, Inci-dence, and Outcomes. Hepatology, 64, 1388-1389.
https://doi.org/10.1002/hep.28584
|
[11]
|
Li, J., Zou, B., Yeo, Y.H., Feng, Y., Xie, X., Lee, D.H., Fujii, H., Wu, Y., Kam, L.Y., Ji, F., Li, X., Chien, N., Wei, M., Ogawa, E., Zhao, C., Wu, X., Stave, C.D., Henry, L., Barnett, S., Takahashi, H., Furusyo, N., Eguchi, Y., Hsu, Y.C., Lee, T.Y., Ren, W., Qin, C., Jun, D.W., Toyoda, H., Wong, V.W. and Cheung, R. (2019) Prevalence, Incidence, and Outcome of Non-Alcoholic Fatty Liver Disease in Asia, 1999-2019: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 4, 389-398. https://doi.org/10.1016/S2468-1253(19)30039-1
|
[12]
|
Cohen, J.C., Horton, J.D. and Hobbs, H.H. (2011) Human Fatty Liver Disease: Old Questions and New Insights. Science, 332, 1519-1523. https://doi.org/10.1126/science.1204265
|
[13]
|
Hall, K.D. and Guo, J. (2017) Obesity Energetics: Body Weight Reg-ulation and the Effects of Diet Composition. Gastroenterology, 152, 1718-1727. https://doi.org/10.1053/j.gastro.2017.01.052
|
[14]
|
孙平. 代谢相关脂肪性肝病膳食干预的前瞻性研究[D]: [硕士学位论文]. 成都: 电子科技大学, 2021.
|
[15]
|
Gao, C., Xu, J., Liu, Y. and Yang, Y. (2021) Nutrition Policy and Healthy China 2030 Building. European Journal of Clinical Nutrition, 75, 238-246. https://doi.org/10.1038/s41430-020-00765-6
|
[16]
|
中国医疗保健国际交流促进会营养与代谢管理分会, 中国营养学会临床营养分会, 中华医学会糖尿病学分会, 中华医学会肠外肠内营养学分会, 中国医师协会营养医师专业委员会. 中国糖尿病医学营养治疗指南(2022版) [J]. 中华糖尿病杂志, 2022, 14(9): 881-933.
|
[17]
|
中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 中华医学会内分泌学分会肝病与代谢学组. 脂肪性肝病诊疗规范化的专家建议(2019年修订版) [J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
|
[18]
|
胡鑫才, 黄小冬. 基于现代文献的针灸治疗非酒精性脂肪肝选穴规律研究[J]. 中医临床研究, 2019, 11(31): 7-11.
|
[19]
|
崔滋欣, 潘甜甜, 李佳韵, 魏佩瑶, 叶峰. 针灸治疗非酒精性脂肪性肝病临床疗效Meta分析[J]. 中国肝脏病杂志(电子版), 2021, 13(1): 10-16.
|
[20]
|
钟培玲, 刘林华, 贺劲松. 针灸治疗非酒精性脂肪性肝病的研究进展[J]. 广州中医药大学学报, 2022, 39(3): 727-734.
|
[21]
|
谢文强. 穴位埋线治疗重度非酒精性脂肪肝患者的临床疗效观察[J]. 江西中医药大学学报, 2022, 34(4): 64-66.
|
[22]
|
李永丰, 谢冬梅, 姚立红, 麻飞玲. 穴位微创埋线治疗非酒精性脂肪性肝病的临床研究[J]. 中西医结合肝病杂志, 2019, 29(6): 550-551+558.
|
[23]
|
高思婷, 冯琴. 非酒精性脂肪肝的中医特色疗法——穴位埋线[J]. 肝博士, 2022(5): 49-50.
|
[24]
|
李军祥, 陈润花, 苏冬梅, 李立. 中医药治疗非酒精性脂肪性肝病研究述评[J]. 世界华人消化杂志, 2010, 18(14): 1443-1451.
|
[25]
|
朱雅娜, 孙玉凤, 何莉莉, 等. 活血化瘀通络中药合方及拆方对糖尿病脂肪肝大鼠SOCS-3和SREBP-1c的影响[J]. 世界华人消化杂志, 2013, 21(29): 3089-3096.
|
[26]
|
刘永萍, 杨如意. 中西医结合治疗高脂血症脂肪肝疗效观察研究[J]. 心理月刊, 2018(3): 193.
|
[27]
|
史俊玲, 李风娥, 刘玉洁. 泽泻方剂抗家兔动脉粥样硬化形成的实验研究[J]. 河北中医, 2008, 30(5): 530-532.
|
[28]
|
赵宏, 谢晓玲, 万金志. 山药的化学成分及药理研究进展[J]. 今日药学, 2009, 19(3): 49-50.
|
[29]
|
李志强, 曹文富. 山药及其主要活性成分药理作用研究进展[J]. 中国老年学杂志, 2013, 33(8): 1975-1976.
|
[30]
|
郭建利, 张睦清, 韩雪, 等. 丹参不同组分防治大鼠非酒精性脂肪肝模型作用机制的研究[J]. 河北中医药学报, 2012, 27(1): 8-9.
|
[31]
|
古宁艳, 杨少军. 中医药防治脂肪肝实验研究进展[J]. 中国中医药信息杂志, 2012, 19(4): 111-112.
|
[32]
|
刘超, 张学武. 黄芪对高脂血症小鼠血脂及脂质过氧化物的影响[J]. 时珍国医国药, 2007, 18(7): 1648-1649.
|
[33]
|
陈莉, 何立英, 金鑫. 麦冬多糖对脂肪细胞胰岛素敏感性的作用机制[J]. 武警后勤学院学报, 2013, 22(1): 5-8.
|
[34]
|
季光. 中医药治疗非酒精性脂肪性肝病敲响国际学术大门[J]. 中西医结合肝病杂志, 2021, 31(6): 484-488.
|